The Food and Drug Administration yesterday released revised draft guidance for facilities that compound human drugs as outsourcing facilities. “We’ve heard the feedback from stakeholders to our proposed 2014 draft guidance that certain [current good manufacturing practice] policies would have made it difficult for outsourcing facilities to fill smaller orders and that some compounded drug products that practitioners requested for office stock were not available from outsourcing facilities due to those policies,” said FDA Commissioner Scott Gottlieb, M.D. “We want to advance policies that make it more feasible for outsourcing facilities to fulfill requests for office stock while maintaining product quality. This revised draft guidance includes changes intended to help achieve this goal, particularly through revisions related to release testing, stability testing and beyond-use dating, as well as policies that differentiate between production of sterile and non-sterile drug products.”

Related News Articles

Headline
The AHA today submitted to the Food and Drug Administration legislative, regulatory and best practice recommendations to address new and chronic prescription…
Headline
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists, and Institute for Safe…
Headline
The Food and Drug Administration yesterday warned the health care community about complications that arise when pairing pain medications with intrathecal…
Headline
Oct. 27 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired prescription pills at sites…
Headline
The Food and Drug Administration yesterday released a series of guidance documents intended to help manufacturers develop generic transdermal and topical…
Headline
The National Academies of Sciences, Engineering and Medicine has released a report summarizing its Sept. 5-6 workshop on medical drug shortages during…